PD‐L1 expression has been demonstrated in many cancers such as breast and ovarian cancers, pancreatic and esophagus adenocarcinoma, kidney and bladder cancers, lung cancers, melanoma, as well as hematologic malignancies, with evidence of associations with clinicopathological factors and prognosis.6, 12. This evidence concerns the gene CD274 and melanoma.